All Releases
Ligand Pharmaceuticals Announces First Quarter Results
May 1, 2008
|
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
Apr 24, 2008
|
Ligand to Hold First Quarter Results Conference Call on May 1
Apr 21, 2008
|
Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA(R) NDA
Mar 3, 2008
|
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Feb 20, 2008
|
Ligand to Hold Fourth Quarter Results Conference Call on February 20
Feb 12, 2008
|
Ligand to Present at BIO CEO and Investor Conference on February 12
Feb 5, 2008
|
Ligand Partner Pfizer Submits NDA for Fablyn(R)
Jan 15, 2008
|
Ligand Pharmaceuticals Awarded U.S. Patent for LGD-4665
Jan 8, 2008
|
Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for PROMACTA(R) (eltrombopag)
Dec 20, 2007
|
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
Dec 8, 2007
|
Ligand Pharmaceuticals Announces Third Quarter Results
Nov 8, 2007
|
Ligand to Hold Third Quarter Results Conference Call on November 8
Nov 1, 2007
|
Ligand to Present at Acumen BioFin Rodman & Renshaw Health Conference on November 5
Nov 1, 2007
|
Ligand Earns Milestone Payment as Wyeth Submits European Market Authorization for Bazedoxifene
Oct 15, 2007
|
Ligand Research Published in Journal of Medicinal Chemistry: LGD-2941 Shows Promise in Treating Muscle and Bone Loss
Oct 10, 2007
|
Ligand to Ring Opening Bell at NASDAQ Stock Market Ceremony
Sep 25, 2007
|
Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
Sep 17, 2007
|
Ligand to Present at Thomas Weisel Partners and Bear Stearns Healthcare Conferences in September
Sep 4, 2007
|
Ligand Pharmaceuticals Announces Second Quarter Results
Aug 8, 2007
|
|
|